Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9924303 | 0.85 | HTT (0.50) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL2698205 | 0.85 | PABPC1 (0.50) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL9910478 | 0.84 | NPC1 (0.48) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL30421806 | 0.84 | NPC1 (0.48) | NPC1POLBMAPTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2698455 | 0.82 | NPC1 (0.47) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL1163268 | 0.81 | NPC1 (0.49) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL16148241 | 0.80 | PABPC1 (0.56) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL2496975 | 0.80 | ALOX15 (0.56) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL13227687 | 0.80 | HTT (0.46) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL1538451 | 0.77 | NPC1 (0.57) | NPC1POLBMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576568-A1 | AN AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITOR OF C-MET PROTEIN KINASE | Vertex Pharmaceuticals Incorporated (US) | 2013-04-10 | — | — | EP | claimed |
| US-8263777-B2 | Aminopyrazole triazolothiadiazole inhibitor of c-Met protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-11 | — | — | US | claimed |
| WO-2011149878-A1 | AN AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITOR OF C-MET PROTEIN KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-01 | — | — | WO | claimed |
| US-20110294849-A1 | AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITOR OF C-MET PROTEIN KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-01 | — | — | US | claimed |
| US-8629144-B2 | Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-14 | — | — | US | disclosed |
| EP-2435443-B1 | AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTIEN KINASE | VERTEX PHARMA (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2576568-A1 | AN AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITOR OF C-MET PROTEIN KINASE | Vertex Pharmaceuticals Incorporated (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20130018072-A1 | AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTEIN KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-17 | — | — | US | disclosed |
| US-8269012-B2 | Aminopyrazole triazolothiadiazole inhibitors of c-met protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-18 | — | — | US | disclosed |
| US-8263777-B2 | Aminopyrazole triazolothiadiazole inhibitor of c-Met protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2435443-A1 | AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTIEN KINASE | Vertex Pharmaceuticals Incorporated (US) | 2012-04-04 | — | — | EP | disclosed |
| WO-2011149878-A1 | AN AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITOR OF C-MET PROTEIN KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110294849-A1 | AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITOR OF C-MET PROTEIN KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110124684-A1 | AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTIEN KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-26 | — | — | US | disclosed |
| WO-2010138665-A1 | AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTIEN KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100197912-A1 | Polymorphic and hydrate forms, salts and process for preparing 6-quinoline | JANSSEN PHARMACEUTICA NV | 2010-08-05 | — | — | US | disclosed |
| EP-2170894-A1 | POLYMORPHIC AND HYDRATE FORMS, SALTS AND PROCESS FOR PREPARING 6-{DIFLUORO[6-(1-METHYL-1H-PYRAZOL-4-YL)[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-3-YL]METHYL}QUINOLINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008155378-A1 | POLYMORPHIC AND HYDRATE FORMS, SALTS AND PROCESS FOR PREPARING 6-{DIFLUORO[6-(1-METHYL-1H-PYRAZOL-4-YL)[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-3-YL]METHYL}QUINOLINE | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124684-A1 | AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTIEN KINASE | MET, MELK, DMPK | NPC1 3969/4885POLB 4144/4885MAPT 3200/4885 |
| US-20130018072-A1 | AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTEIN KINASE | MET, ABL1, DMPK | NPC1 3477/4885POLB 4082/4885MAPT 2061/4885 |
| US-20100197912-A1 | Polymorphic and hydrate forms, salts and process for preparing 6-quinoline | CYP2D6, UGT1A1, UGT1A6 | NPC1 659/4885POLB 1351/4885MAPT 2199/4885 |
| US-20110294849-A1 | AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITOR OF C-MET PROTEIN KINASE | MET, ABL1, DMPK | NPC1 4203/4885POLB 3657/4885MAPT 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.